April 4, 2007
Stelios T. Andreadis, Ph.D.
Stelios T. Andreadis, Ph.D., received his B.S. degree in Chemical Engineering from the Aristotle University of Thessaloniki, Greece and his M.S and Ph.D. degrees from the University of Michigan, Ann Arbor. Following his graduate studies, he joined the Center for Engineering in Medicine at Harvard Medical School for two years as a post-doctoral fellow. He is currently Associate Professor of Chemical and Biological Engineering and co-director of the Center for Biomedical Engineering at the State University of New York at Buffalo. He is also holds adjunct appointments in the Departments of Biological Sciences and Dermatology and he is member of the newly founded New York State Center of Excellence in Bioinformatics and Life Sciences. His research include retroviral and lentiviral vectors for gene therapy, adult stem cells for cell therapies, tissue engineering of skin and wound healing and cardiovascular tissue engineering.
Glenn R. Gaudette, Ph.D.
Glenn R. Gaudette, Ph.D. is an Assistant Professor of Biomedical Engineering at Worcester Polytechnic Institute. He received his PhD from SUNY - Stony Brook in 2002, and went directly into a tenure track position there in the Department of Biomedical Engineering with a joint appointment in the Department of Surgery. He was named a James D. Watson Fellow by New York State in 2002. He joined WPI after spending two years in the Department of Surgery/Division of Cardiac Surgery at the University of Massachusetts Medical School where he was also the graduate program director in Biomedical Engineering. His research is focused on cardiac regeneration and cardiovascular biomechanics. In his work, he has been able to induce adult cardiac myocytes to enter the cell cycle and to differentiate adult stem cells into cardiac myocytes. In addition, he developed a method for accurately measuring regional function at very high spatial resolution in the heart. His research is supported by the American Heart Association and the National Institutes of Health.
Ronald A. Ignotz, Ph.D.
Dr. Ignotz received a Ph.D. in Cell Biology at the University of Pittsburgh School of Medicine. He joined Dr. Joan Massague's laboratory as a post-doctoral fellow in biochemistry at the University of Massachusetts Medical School. Following his postdoctoral training, Dr. Ignotz joined the Cell Biology Department as an Assistant Professor where his laboratory studied the biology of Transforming Growth Factor-Beta. He subsequently joined the Tissue Engineering group and currently is a Research Scientist in Surgery at the University of Massachusetts Medical School. Current research involves understanding the pathology of chronic wounds and the used of collagen matrices for surgical repair and tissue regeneration. Dr. Ignotz is the author of more that 25 peer reviewed publications.
Peter Johnson, MD
Peter Johnson, MD is the President and CEO of Scintellix, LLC, a biomedical technology consulting company in Raleigh, NC. He was educated at the University of Notre Dame and the SUNY Upstate Medical University. He completed General Surgery and Plastic Surgery residencies at Case-Western Reserve University and the University of Pittsburgh, respectively. He took a postdoctoral fellowship in thrombosis biology at Harvard University. He practiced reconstructive surgery for ten years on the University of Pittsburgh faculty where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative, after which he co-founded and was CEO of TissueInformatics.Inc. Prior to founding Scintellix, he served as Chief Medical Officer, Executive Vice President of Life Sciences and Chief Business Officer of Icoria, Inc. Dr. Johnson is a past President of the Plastic Surgery Research Council, the Pennsylvania Biotechnology Association, the Tissue Engineering Society, International and is presently the Co-Editor-in-Chief of the Journal, Tissue Engineering. He serves on the Board of Trustees of Carnegie Mellon University, the Pittsburgh Tissue Engineering Initiative, EADevices, Inc., Microscience group, and the Advanced Regenerative Tissue Engineering Center (ARTEC) in Toronto, ON.
Louis M. Messina, M.D.
Louis M. Messina, M.D. Professor and Chief of Vascular Surgery, University of Massachusetts Medical School. He graduated Summa Cum Laude from SUNY Downstate Medical School. He completed training in both General Surgery and Vascular Surgery at the University of California San Francisco. He completed a two year research fellowship in the Cardiovascular Research Institute at UCSF as well. He spent 10 years on the faculty of the University of Michigan where he practiced vascular surgery and pursued research on the regeneration of the microcirculation of skeletal muscle using intravital microscopy. In 1995, he returned to UCSF as Chief of Vascular Surgery. He research shifted toward elucidating the mechanisms regulating collateral artery enlargement in rat and mouse models of limb ischemia. This research focus continues and is currently centered on how risk factors such as hypercholesterolemia and diabetes affect the cellular and molecular mechanisms regulating collateral artery enlargement. Much of this work centers on the expression of endothelial nitric oxide synthase and the bioavailability of nitric oxide and how changes in redox stress effects these variables. Most recently, the role of bone marrow derived cells in the process of arteriogenesis. The long term goal of this research program is to develop a molecular therapy to increase collateral artery enlargement.Maintained by email@example.com
Last modified: April 19, 2007 11:22:32